Key facts
- Notable investors include Tailong VC, Hangzhou Oufang Venture Capital Management, Taikun Fund, Dian Diagnostics, Guangzhou Hi-tech Investment Group — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for PathoAI
- ·The full record, as it builds
Funding rounds
No funding rounds for PathoAI are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About PathoAI
Provider of precision pathology solutions created to provide patients with accurate diagnoses and thereon avail them to effective treatments by using AI focused technology. The company uses AI-powered technology to the next generation automation that unlocks scientific insights through the intimate study of pathology samples, enabling doctors to effectively optimize patient outcomes.
- Sector
- Information Technology
- HQ
- Hangzhou, China
- Founded
- 2021
- Website
- pathoai.com/
- Ownership
- Privately Held (backing)
PathoAI doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in PathoAI shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on PathoAI in its N-PORT filings yet. We sweep new filings monthly.